Literature DB >> 1984664

The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes.

O K Haffar1, D J Dowbenko, P W Berman.   

Abstract

The HIV-1 envelope glycoprotein gp160 associates with cellular membranes via a discrete transmembrane domain. Unlike other retroviral envelope proteins, however, gp160 also forms a secondary association with the lipid bilayer mediated by one or more regions located in the cytoplasmic tail. We have expressed the full cytoplasmic tail sequence of gp160, as a fusion protein with the HSV-1 glycoprotein D signal sequence, transiently in a human embryonic kidney cell line. Our results show that in the absence of any defined transmembrane domain or stop transfer sequence, the protein corresponding to the cytoplasmic tail of HIV-1 gp160 formed stable interactions with cellular membranes that mediated its export to the cell surface.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984664     DOI: 10.1016/0042-6822(91)90054-f

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

1.  Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity.

Authors:  S C Piller; J W Dubay; C A Derdeyn; E Hunter
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 3.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

4.  Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription.

Authors:  H Zhang; G Dornadula; P Alur; M A Laughlin; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

5.  Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

Authors:  Sara M O'Rourke; Becky Schweighardt; Pham Phung; Kathryn A Mesa; Aaron L Vollrath; Gwen P Tatsuno; Briana To; Faruk Sinangil; Kay Limoli; Terri Wrin; Phillip W Berman
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

6.  Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein.

Authors:  Vanessa Emerson; Denise Holtkotte; Tanya Pfeiffer; I-Hsuan Wang; Martina Schnölzer; Tore Kempf; Valerie Bosch
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

Authors:  G D Ritter; G Yamshchikov; S J Cohen; M J Mulligan
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.

Authors:  J W Dubay; S J Roberts; B H Hahn; E Hunter
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 9.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Authors:  G R Nakamura; R Byrn; D M Wilkes; J A Fox; M R Hobbs; R Hastings; H C Wessling; M A Norcross; B M Fendly; P W Berman
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.